India
· Delayed Price · Currency is INR Eris Lifesciences Statistics
Total Valuation
Eris Lifesciences has a market cap or net worth of INR 187.87 billion. The enterprise value is 216.85 billion.
| Market Cap | 187.87B |
| Enterprise Value | 216.85B |
Important Dates
The next estimated earnings date is Tuesday, January 21, 2025.
| Earnings Date | Jan 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 40.79M |
Valuation Ratios
The trailing PE ratio is 53.91.
| PE Ratio | 53.91 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 25.88, with an EV/FCF ratio of 36.56.
| EV / Earnings | 62.23 |
| EV / Sales | 8.73 |
| EV / EBITDA | 25.88 |
| EV / EBIT | 37.10 |
| EV / FCF | 36.56 |
Financial Position
The company has a current ratio of 1.07, with a Debt / Equity ratio of 0.86.
| Current Ratio | 1.07 |
| Quick Ratio | 0.59 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | 3.26 |
| Debt / FCF | 4.61 |
| Interest Coverage | 3.42 |
Financial Efficiency
Return on equity (ROE) is 13.09% and return on invested capital (ROIC) is 7.97%.
| Return on Equity (ROE) | 13.09% |
| Return on Assets (ROA) | 6.71% |
| Return on Capital (ROIC) | 7.97% |
| Revenue Per Employee | 6.87M |
| Profits Per Employee | 962,605 |
| Employee Count | 3,620 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 2.99 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +55.49% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +55.49% |
| 50-Day Moving Average | 1,380.66 |
| 200-Day Moving Average | 1,134.94 |
| Relative Strength Index (RSI) | 42.04 |
| Average Volume (20 Days) | 8,415 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Eris Lifesciences had revenue of INR 24.85 billion and earned 3.48 billion in profits. Earnings per share was 25.58.
| Revenue | 24.85B |
| Gross Profit | 18.95B |
| Operating Income | 5.85B |
| Pretax Income | 4.37B |
| Net Income | 3.48B |
| EBITDA | 8.26B |
| EBIT | 5.85B |
| Earnings Per Share (EPS) | 25.58 |
Balance Sheet
The company has 2.43 billion in cash and 27.35 billion in debt, giving a net cash position of -24.92 billion.
| Cash & Cash Equivalents | 2.43B |
| Total Debt | 27.35B |
| Net Cash | -24.92B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 31.77B |
| Book Value Per Share | 203.65 |
| Working Capital | 833.80M |
Cash Flow
In the last 12 months, operating cash flow was 7.07 billion and capital expenditures -1.14 billion, giving a free cash flow of 5.93 billion.
| Operating Cash Flow | 7.07B |
| Capital Expenditures | -1.14B |
| Free Cash Flow | 5.93B |
| FCF Per Share | n/a |
Margins
Gross margin is 76.25%, with operating and profit margins of 23.52% and 14.02%.
| Gross Margin | 76.25% |
| Operating Margin | 23.52% |
| Pretax Margin | 17.58% |
| Profit Margin | 14.02% |
| EBITDA Margin | 33.24% |
| EBIT Margin | 23.52% |
| FCF Margin | 23.87% |
Dividends & Yields
Eris Lifesciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.02% |
| Shareholder Yield | -0.02% |
| Earnings Yield | 1.86% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |